ClinicalTrials.gg
RecruitingNCT06733740Updated Feb 14, 2025

Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma

An observational study in Papillary Thyroid Cancer, sponsored by Chinese PLA General Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by Chinese PLA General Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Thyroid Cancer, Papillary with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Thyroid Cancer, Papillary · China.

Planned enrollment
3rd of 19
3,000 · median 541
Started
2024
with 9 others
Observational
19 of 40
15 open now
Primary completion
2028-12
later than 22 of 24 live
Registered
31st of 40
by date
Lead sponsor
3 of 40
Chinese PLA General Hospital

Among the 40 studies in Thyroid Cancer, Papillary with a site in China, this one is the 3rd largest by planned enrollment of the 19 observational ones that give a count, is one of 10 that started in 2024, is one of 19 observational ones, reaches primary completion later than 22 of the 24 other live ones, and was the 31st registered.

Thyroid Cancer, Papillary

187 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.

Browse Thyroid Cancer, Papillary studies →

Open to participants now

24 of the 40 studies in Thyroid Cancer, Papillary with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Thyroid Cancer, Papillary with a site in China, or all of them as a file.
02

Study summary

To evaluate long-term outcomes of ultrasound-guided thermal ablation for the treatment of papillary thyroid carcinoma

Read the detailed description

To evaluate and predict long-term clinical outcomes of ultrasound-guided thermal ablation for the treatment of papillary thyroid carcinoma by a multicenter study

03

Conditions studied

  • Papillary Thyroid Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with papillary thyroid carcinoma who refuse surgery or active surveillance and choose thermal ablation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients age between 18 and 80 year old, both sex
  2. papillary thyroid carcinoma confirmed by core-needle or fine-needle aspiration
  3. the largest diameter ≤2.0 cm
  4. no clinical or imaging evidences of extrathyroidal extension, lymph node and distant metastasis on ultrasound, neck and chest CT
  5. follow-up period ≥12 months

Exclusion criteria

Exclusion Criteria:

  1. patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by
  2. history of neck radiation
  3. coagulation disorder, serious heart, respiratory, liver, or renal failure
  4. dysfunction of the vocal cord on the opposite side
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Interventions

  • Procedureultrasound-guided thermal ablation

    ultrasound-guided thermal ablation to treat tumor

06

What researchers measure

Primary outcomes

  1. rate of disease progression

    cervical lymph node metastases, recurrent tumors and persistent tumors confirmed by pathology

    Time frame: through study completion, an average of 6 months

Secondary outcomes

  1. Rate of complications

    complications of ablation

    Time frame: 1 week

  2. Rate of tumor disappearance

    complete disappearance of ablated tumor on ultrasound and contrast-enhanced ultrasound

    Time frame: through study completion, an average of 6 months

  3. Rate of volume reduction

    volume reduction of tumor after ablation on ultrasound and contrast-enhanced ultrasound

    Time frame: through study completion, an average of 6 months

  4. rate of change of thyroid function

    thyroid function test, including free triiodothyronine, free thyroxine, thyroid stimulating hormone, thyroid peroxidase antibody and anti-thyroglobulin antibodies

    Time frame: through study completion, an average of 6 months

  5. rate of delayed surgery

    patients underwent surgery after ablation because of anxiety

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2028, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Dec 13, 2024
StartActual
Dec 10, 2024
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06733740
Responsible party
Yu-kun Luo (Clinical Professor, Chinese PLA General Hospital) — Principal investigator
First posted
Dec 13, 2024
Start date
Dec 10, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Feb 14, 2025

Study contacts

Lin Yan, MD
Contact
gemma-y@163.com
13811237313 ext 86
Yukun Luo
principal investigator · Chinese PLA General Hospital
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion